Devonian Health Group has received authorisation from Health Canada for its CTA to begin a Phase II/III study of Thykamine cream to treat mild-to-moderate atopic dermatitis in paediatric patients.

The post Devonian’s Phase II/III Thykamine paediatric study secures Health Canada approval appeared first on Clinical Trials Arena.